hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06352554, orgStudyIdInfo id: 2023/ETH02474:STING, secondaryIdInfos id: 224842/Z/21/Z, type: OTHER_GRANT, domain: Wellcome Trust, secondaryIdInfos id: 75A50122C00028, type: OTHER_GRANT, domain: HHS/BARDA OTA, briefTitle: Susceptibility Testing In Neisseria Gonorrhoeae (STING) Study, Assessing the Performance of a New Rapid Test for Gonorrhoea Antibiotic Resistance, in a Cohort of 100 Culture Positive Neisseria Gonorrhoeae Infections, acronym: STING, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-08, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2025-01-30, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: SpeeDx Pty Ltd, class: INDUSTRY, collaborators name: Biomedical Advanced Research and Development Authority, collaborators name: Wellcome Trust, collaborators name: German Federal Ministry of Education and Research, collaborators name: Australian Research Council Research Hub to Combat Antimicrobial Resistance, descriptionModule briefSummary: This study aims to validate a novel antibiotic susceptibility test (InSignia) for gonorrhoea in patient clinical samples.The hypothesis is that the InSignia test will be able to detect transcriptional responses after incubation in antibiotic for susceptible strains and not resistant strains.Furthermore, this study will also add to our understanding on the performance of this test in various clinical specimens., conditionsModule conditions: Diagnosis, conditions: Gonorrhea, conditions: Resistance Bacterial, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 100, type: ESTIMATED, outcomesModule primaryOutcomes measure: To determine the feasibility of performing antibiotic susceptibility testing (AST) for Neisseria gonorrhoeae directly from patient samples using InSignia workflow and assay against commonly used & clinically relevant antibiotics., secondaryOutcomes measure: To study the performance of the InSignia assay in determining antibiotic susceptibility of NG against commonly used & clinically relevant agents in clinical samples with comparison to gold standard methods., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06352541, orgStudyIdInfo id: SOPH232-1122/I, briefTitle: Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo., acronym: PRO-232, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-30, primaryCompletionDateStruct date: 2025-06-30, completionDateStruct date: 2025-06-30, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Laboratorios Sophia S.A de C.V., class: INDUSTRY, descriptionModule briefSummary: This is a phase I study evaluating safety and tolerability through the incidence of unexpected adverse events and IOP measurement, as well as through the incidence of stinging after its administration, compared to placebo., conditionsModule conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Phase I, controlled, comparative, parallel groups, double blind, one center., primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, maskingDescription: Double blind., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 34, type: ESTIMATED, armsInterventionsModule interventions name: PRO-232, interventions name: Placebo, outcomesModule primaryOutcomes measure: Incidence Unexpected Related Adverse Reactions, primaryOutcomes measure: Changes in intraocular pressure (IOP), primaryOutcomes measure: Incidence of Stinging, secondaryOutcomes measure: Incidence of Expected Related Adverse Events, secondaryOutcomes measure: Changes in Best Corrected Visual Acuity (BCVA), secondaryOutcomes measure: Changes in the integrity of the ocular surface (fluorescein staining), secondaryOutcomes measure: Incidence of ocular symptoms (foreign body sensation and tearing), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06352528, orgStudyIdInfo id: CA127-1070, briefTitle: A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-26, primaryCompletionDateStruct date: 2025-07-24, completionDateStruct date: 2025-07-24, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Bristol-Myers Squibb, class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to assess the drug levels of a single oral dose of repotrectinib in participants with moderate and severe HI, and in healthy matched control participants with normal hepatic function., conditionsModule conditions: Hepatic Impairment, conditions: Healthy Volunteers, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: Repotrectinib, outcomesModule primaryOutcomes measure: Maximum observed plasma concentration (Cmax), primaryOutcomes measure: Time of maximum observed plasma concentration (Tmax), primaryOutcomes measure: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)), primaryOutcomes measure: Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF)), secondaryOutcomes measure: Number of participants with Adverse Events (AEs), secondaryOutcomes measure: Number of participants with Severe Adverse Events (SAEs), secondaryOutcomes measure: Number of participants with physical examination abnormalities, secondaryOutcomes measure: Number of participants with vital sign abnormalities, secondaryOutcomes measure: Number of participants with electrocardiogram (ECG) abnormalities, secondaryOutcomes measure: Number of participants with clinical safety laboratory test abnormalities, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Local Institution - 0003, city: Miami Lakes, state: Florida, zip: 33014, country: United States, contacts name: Site 0003, role: CONTACT, geoPoint lat: 25.90871, lon: -80.30866, locations facility: Local Institution - 0001, city: Orlando, state: Florida, zip: 32809, country: United States, contacts name: Site 0001, role: CONTACT, geoPoint lat: 28.53834, lon: -81.37924, locations facility: Local Institution - 0002, city: San Antonio, state: Texas, zip: 78215, country: United States, contacts name: Site 0002, role: CONTACT, geoPoint lat: 29.42412, lon: -98.49363, hasResults: False
protocolSection identificationModule nctId: NCT06352515, orgStudyIdInfo id: T cells in Ulcerative colitis, briefTitle: T Lymphocyte Subsets in Ulcerative Colitis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2026-06-01, completionDateStruct date: 2027-06-01, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: 1. Study the distribution of peripheral blood T lymphocyte subsets among ulcerative colitis patients.2. Correlation of T-cell subsets to therapeutic response/ disease activity.3. Assess the value of circulating IgG anti-Integrin αvβ6 in UC., conditionsModule conditions: Ulcerative Colitis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Flow cytometry, outcomesModule primaryOutcomes measure: Study the distribution of T-cell subsets among ulcerative colitis patients., primaryOutcomes measure: Correlation of T-cell subtypes to therapeutic response, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06352502, orgStudyIdInfo id: 202112-28, briefTitle: An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-01-28, primaryCompletionDateStruct date: 2024-09-30, completionDateStruct date: 2024-09-30, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Tang-Du Hospital, class: OTHER, descriptionModule briefSummary: EGFR mutation positive advanced NSCLC patients with CNS metastases were associated with poor prognosis. Furmonertinib showed promising CNS efficacy in doses of 80 mg orally once daily or higher in patients with EGFR T790M mutation positive NSCLC. This study aims to investigate the efficacy and safety of furmonertinib in the treatment of EGFR-sensitive mutation positive NSCLC patients with brain metastasis., conditionsModule conditions: EGF-R Positive Non-Small Cell Lung Cancer, conditions: CNS Metastases, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Furmonertinib, outcomesModule primaryOutcomes measure: Intracranial Objective response rate, primaryOutcomes measure: Intracranial Disease Control Rate, primaryOutcomes measure: Intracranial progression-free survival, secondaryOutcomes measure: Progression-free survival, secondaryOutcomes measure: Overall Survival, secondaryOutcomes measure: Safety/Adverse event, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tangdu Hopspital, status: RECRUITING, city: Xi'an, state: Shanxi, zip: 710038, country: China, contacts name: Haichuan Su, PhD, role: CONTACT, phone: 18629190366, email: such@fmmu.edu.cn, contacts name: Jie Min, PhD, role: CONTACT, phone: 13709202616, email: minjie1504@163.com, contacts name: Haichuan Su, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Jie Min, PhD, role: SUB_INVESTIGATOR, geoPoint lat: 34.25833, lon: 108.92861, hasResults: False
protocolSection identificationModule nctId: NCT06352489, orgStudyIdInfo id: Posterior component separation, briefTitle: Evaluation of Posterior Component Separation Technique in the Management of Complex Ventral Hernia., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-05, completionDateStruct date: 2026-06, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: * Assess short term outcome of posterior component separation technique(PCS) including the regain of the physiological function of the abdominal wall.* Detect most common post operative complications related to AWR techniques in a 6 months duration after operation., conditionsModule conditions: Ventral Hernia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Posterior component separation technique., outcomesModule primaryOutcomes measure: Hernia recurrence, secondaryOutcomes measure: post operative short term complications, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06352463, orgStudyIdInfo id: 406.XS.03.068, briefTitle: Intervention Social Anxiety: Combining Parent-child Treatment, acronym: ISA, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2025-07-01, completionDateStruct date: 2025-07-01, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Leiden University, class: OTHER, collaborators name: Leids Universitair Behandel en Expertise Centrum (LUBEC), collaborators name: GGZ Delfland, collaborators name: Netherlands Organisation for Scientific Research, descriptionModule briefSummary: The aim of this pilot project is to investigate a treatment program for children with social anxiety, in which children and their parents, parallel to each other, follow separate evidence-based interventions. The added value of this pilot project is that the investigators are examining how both programs interact when offered simultaneously., conditionsModule conditions: Social Anxiety Disorder of Childhood, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 9, type: ESTIMATED, armsInterventionsModule interventions name: Denken + Doen = Durven, interventions name: Supportive Parenting for Anxious Childhood Emotions, outcomesModule primaryOutcomes measure: Change in severity of social anxiety in children, secondaryOutcomes measure: Change in anxiety-related symptoms and family accommodation, eligibilityModule sex: ALL, minimumAge: 8 Years, maximumAge: 16 Years, stdAges: CHILD, contactsLocationsModule locations facility: GGZ Delfland, status: NOT_YET_RECRUITING, city: Delft, state: South-Holland, zip: 2600GA, country: Netherlands, contacts name: Anika Bexkens, role: CONTACT, email: a.bexkens@fsw.leidenuniv.nl, geoPoint lat: 52.00667, lon: 4.35556, locations facility: Leiden University, status: RECRUITING, city: Leiden, state: South-Holland, zip: 2333AK, country: Netherlands, geoPoint lat: 52.15833, lon: 4.49306, locations facility: LUBEC, status: RECRUITING, city: Leiden, state: South-Holland, zip: 2333ZB, country: Netherlands, contacts name: Anika Bexkens, role: CONTACT, email: a.bexkens@fsw.leidenuniv.nl, geoPoint lat: 52.15833, lon: 4.49306, hasResults: False
protocolSection identificationModule nctId: NCT06352450, orgStudyIdInfo id: DPT/Batch-Fall19/558, briefTitle: Comparison of Active Isolated Stretching Versus Myofascial Release of Knee Joint in Office Workers, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-01-15, primaryCompletionDateStruct date: 2024-05-20, completionDateStruct date: 2024-06-28, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Superior University, class: OTHER, descriptionModule briefSummary: "Office workers often spend long hours sitting, which can lead to stiffness and reduced mobility. By studying these two techniques AIS and MFR, we can determine which one is more effective in helping office workers to improve their flexibility and range of motion in the knee joint because their sedentary work environment often leads to musculoskeletal issues, including limited knee joint mobility.AIS involves stretching specific muscles while actively engaging opposing muscles to enhance the effectiveness of the stretch. It aims to increase the extensibility of muscles and improve joint mobility. On the other hand, MFR focuses on releasing tension and adhesions in the fascia, the connective tissue surrounding muscles and joints, to restore mobility and reduce pain.Understanding the benefits and effectiveness of these techniques will contribute to evidence-based practices in occupational health and help office workers maintain optimal joint health", conditionsModule conditions: Stiffness; Spine, conditions: Mobility Limitation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Active isolated stretching (AIS), interventions name: Myofascial release (MFR), outcomesModule primaryOutcomes measure: Numaric Pain Scale, eligibilityModule sex: ALL, minimumAge: 25 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Al-Zahra Medical complex Johar town, Laser spine center Model town, Laser spine center Johar town., city: Lahore, country: Pakistan, geoPoint lat: 31.558, lon: 74.35071, hasResults: False
protocolSection identificationModule nctId: NCT06352424, orgStudyIdInfo id: 1458-0006, secondaryIdInfos id: 2023-506233-30-01, type: REGISTRY, domain: CTIS (EU), secondaryIdInfos id: U1111-1293-4672, type: REGISTRY, domain: WHO Registry, briefTitle: A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2024-12-09, completionDateStruct date: 2024-12-09, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Boehringer Ingelheim, class: INDUSTRY, descriptionModule briefSummary: The main objective of this trial is to investigate the effect of BI 1820237 alone, BI 456906 alone, combination of BI 1820237 and BI 456906 versus placebo on brain activity., conditionsModule conditions: Obesity, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: BI 456906, interventions name: BI 1820237, interventions name: Placebo for BI 1820237, interventions name: Placebo for BI 456906, outcomesModule primaryOutcomes measure: Blood Oxygen Level Dependent (BOLD) signal changes following treatment with single dose of BI 1820237 alone, BI 456906 alone, and combination of BI 1820237 + BI 456906 versus placebo, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06352398, orgStudyIdInfo id: BBTuysuz, briefTitle: Comparison of Analgesic Efficacy in Video-Assisted Thoracoscopic Surgery Patients, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-12-20, primaryCompletionDateStruct date: 2024-02-01, completionDateStruct date: 2024-04-01, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Burcu Bozdogan Tuysuz, class: OTHER, descriptionModule briefSummary: The 52 patients included in the study were divided into two groups as ESPB (n=26) and SPSIPB (n=26). Before the operation, 0.25% bupivacaine 30 ml was administered to both groups. After admission to the operating room, all patients underwent standard anaesthesia procedures. Morphine 0.05 mg/kg i.v. and parol 1 g i.v. were administered 30 min before the end of the operation. Post operatively the patient was followed up with controlled analgesia. Demographic data, ASA scores, body mass indexes, peri-operative haemodynamic values, remifentanil consumption and duration of surgery were recorded. Post-operative first 24 hours NRS scores, morphine consumption, number of nausea and vomiting episodes were recorded., conditionsModule conditions: Video-Assisted Thoracoscopic Surgery, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 52, type: ACTUAL, armsInterventionsModule interventions name: erector spina plan block, interventions name: Serratus posterior superior intercostal plan block (SPSIPB), interventions name: 0.25% bupivacaine, outcomesModule primaryOutcomes measure: morphine consumption first 24 hours, secondaryOutcomes measure: NRS pain score, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Istanbul Medenıyet Unıversıty, city: Istanbul, state: Kadıkoy, zip: 34734, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06352385, orgStudyIdInfo id: SH9H-2024-TK16-1.0, briefTitle: Epidemiological Investigation of Malocclusion in China, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-12, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Shanghai Jiao Tong University School of Medicine, class: OTHER, descriptionModule briefSummary: Malocclusion is a kind of craniomaxillofacial complex deformity caused by heredity, environment, bad habits, trauma, inflammation, tumor and aging. Notably, the last comprehensive national prevalence data on malocclusion in China, which encompassed a significant sample size, dates back over two decades. Given the evolving nature of these epidemiological metrics, such as prevalence rates, it is imperative to update our understanding. Consequently, there is an urgent need for China to undertake a unified, standardized epidemiological survey of malocclusion with a substantial sample size to ensure accurate and timely data collection., conditionsModule conditions: Epidemiological Investigation, conditions: Malocclusion, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 19847, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: The Prevalence rate of malocclusion, secondaryOutcomes measure: Dental Aesthetic Index of each age group, secondaryOutcomes measure: Index of Orthodontic Treatment Need of each age group, otherOutcomes measure: dietary habit, otherOutcomes measure: oral hygiene habits, otherOutcomes measure: Bad oral habit, eligibilityModule sex: ALL, minimumAge: 4 Years, maximumAge: 20 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False